TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27745535
Drug: Usual outpatient
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual outpatient mental health treatment
Study: 25901477
Drug: Opioid +
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid + pain (intravenous fentanyl 1 μg/kg and cold-pressor pain)
Study: 25901477
Drug: Opioid only
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid only (intravenous fentanyl 1 μg/kg)
Study: 26346805
Drug: Initial Conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial Conservative Treatment
Study: 2045530
Drug: Captopril (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (0.7 mg/kg for young, 1.2 mg/kg for elderly)
Study: 6861601
Drug: Phenobarbital 5
Normalized name: phenobarbital 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 5 mg/kg/day for 5 to 12 months
Study: 29768147
Drug: Budesonide-formoterol used
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-formoterol used as needed (200 μg of budesonide and 6 μg of formoterol)
Study: 29768147
Drug: Budesonide maintenance
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide maintenance therapy (200 μg of budesonide plus terbutaline 0.5 mg used as needed)
Study: 29768147
Drug: Budesonide maintenance
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide maintenance therapy
Study: 27001560
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine treatment and care)
Study: 23157902
Drug: Clopidogrel combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel combined with warfarin (group B)
Study: 17106432
Drug: Gabapentin 1800
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1800 mg daily
Study: 23997137
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression (IPC) of the foot for at least six hours daily under a plaster cast for two weeks
Study: 8878342
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg, acute dose)
Study: 8878342
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day for 14 days, chronic dose)
Study: 27741345
Drug: Efinaconazole topical
Normalized name: efinaconazole topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efinaconazole topical solution (10%)
Study: 24038028
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of corticosteroid
Study: 20028946
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glucose infusion (euglycemic-hyperinsulinemic clamp)
Study: 20028946
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glucose infusion plus Intralipid and heparin infusion
Study: 17010005
Drug: Naftopidil monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil monotherapy (25-75 mg/day)
Study: 17010005
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (25-75 mg/day of naftopidil and 10-20 mg/day of propiverine hydrochloride or 2-6 mg/day of oxybutynin hydrochloride)
Study: 12705171
Drug: 0.05% azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% azelastine eye drops, twice daily
Study: 10632236
Drug: Sertraline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (up to 200 mg/d)
Study: 10632236
Drug: Desipramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (up to 300 mg/d)
Study: 11788107
Drug: 20-40 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-40 mg/day lovastatin
Study: 1330434
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day (minidose) warfarin
Study: 1330434
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 20-40 mg/day lovastatin and 1 mg/day warfarin
Study: 1330434
Drug: Warfarin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin placebo
Study: 1330434
Drug: Low-dose (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (81 mg/day) aspirin
Study: 19243753
Drug: Combination hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination hormone therapy (HT), 5 microg ethinyl E(2) and 1 mg norethindrone acetate for 4 weeks
Study: 15819765
Drug: Diamorphine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 0.25 mg (D)
Study: 15819765
Drug: Fentanyl 15
Normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 15 microg plus diamorphine 0.25 mg (FD)
Study: 11899505
Drug: Albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusion with large-volume paracentesis
Study: 11899505
Drug: Albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusion in selected patients
Study: 11899505
Drug: Albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusion with vasopressin analogue
Study: 10980827
Drug: Secondary preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary preventive therapies (statin drugs and aspirin)
Study: 7669490
Drug: R 56865
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 56865 (20 mg)
Study: 7669490
Drug: R 56865
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 56865 (30 mg)
Study: 7669490
Drug: R 56865
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 56865 (40 mg)
Study: 2288834
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of eltoprazine (8 mg)
Study: 2288834
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of eltoprazine (3 mg)
Study: 2288834
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of eltoprazine (8 mg)
Study: 7026073
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus mastectomy (surgery)
Study: 7026073
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (chemotherapy plus mastectomy and chemotherapy plus radiotherapy)
Study: 7026073
Drug: Surgical group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical group (chemotherapy plus mastectomy)
Study: 21078950
Drug: PNU-100480 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-100480 at 600 mg twice daily for 28 days
Study: 21078950
Drug: Linezolid at
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid at 300 mg daily for 4 days
Study: 21382958
Drug: Polarity Therapy
Normalized name: Adlarity
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polarity Therapy (PT)
Study: 12014063
Drug: Fexofenadine 180
Normalized name: fexofenadine 180 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 180 mg OD for 3 weeks followed by randomization to fexofenadine or placebo for another 3 weeks
Study: 10221688
Drug: Trimegestone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimegestone (various doses) with micronized oestradiol (2 mg/day)
Study: 16903597
Drug: Scraping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping therapy and warming acupuncture-moxibustion
Study: 6315050
Drug: Wholemeal bread
Normalized name: Wholemeal bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wholemeal bread (phytate 2.2 mmol, non-starch polysaccharide 18.7 g)
Study: 6315050
Drug: Brown bread
Normalized name: Brown bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brown bread (phytate 2.1 mmol, non-starch polysaccharide 10.9 g)
Study: 6315050
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread (phytate 2.3 mmol, non-starch polysaccharide 3.3 g)
Study: 29428473
Drug: Blood loss
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood loss ≥500 mL
Study: 26374448
Drug: Leptin antagonist
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin antagonist (in vitro experiments)
Study: 19180337
Drug: Oscillating positive
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating positive expiratory pressure maneuvers followed by forced expiratory technique sequences with inhaled hypertonic saline (3%, 4% or 5%) in asthma patients (A/I)
Study: 19180337
Drug: Oscillating positive
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating positive expiratory pressure maneuvers followed by forced expiratory technique sequences with inhaled hypertonic saline (3%, 4% or 5%) in COPD patients (C/I)
Study: 12462513
Drug: Nonpharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological treatment (vagal tone increase)
Study: 12462513
Drug: Nonpharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological treatment (little change in vagal tone)
Study: 10690132
Drug: Omitting ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omitting ACE inhibitor medication before surgery
Study: 10690132
Drug: Continuing ACE
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing ACE inhibitor medication before surgery
Study: 1984377
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg epidural morphine with 3 mL of normal saline (group 1)
Study: 1984377
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg epidural morphine with 1 mg butorphanol and 2 mL of normal saline (group 2)
Study: 1984377
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg epidural morphine with 3 mg butorphanol (group 3)
Study: 25087057
Drug: Droperidol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (75 mcg/kg) administered after cardiopulmonary bypass
Study: 23474908
Drug: Ticagrelor with
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor with low-dose acetylsalicylic acid (ASA) (≤150 mg)
Study: 23474908
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with low-dose acetylsalicylic acid (ASA) (≤150 mg)
Study: 21704242
Drug: Etamicastat 100
Normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat 100 mg single dose
Study: 21704242
Drug: Etamicastat 100
Normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat 100 mg/day for 7 days
Study: 21704242
Drug: Etamicastat single
Normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat single dose
Study: 19428083
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg/d orally for 3 months
Study: 12426514
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg orally once daily for 5 days (phase 2)
Study: 23904065
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (11 infants)
Study: 23276234
Drug: Individual Placement
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Placement and Support + treatment as usual
Study: 20189226
Drug: Doxazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2 mg daily at night) along with diclofenac sodium 50 mg
Study: 16146478
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of bupivacaine (20 ml of 2.5 mg/ml) 30 min before skin incision
Study: 16146478
Drug: Post-operative administration
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative administration of bupivacaine (20 ml of 2.5 mg/ml) after skin closure
Study: 12182256
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1%/benzoyl peroxide 5% gel formulation
Study: 12182256
Drug: Clindamycin 1%
Normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1% gel (monotherapy)
Study: 10202871
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of clomiphene citrate on days 1-5 and placebo on days 5-9
Study: 8539022
Drug: Dapiprazole 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapiprazole 0.5% ophthalmic solution
Study: 2222553
Drug: Placebo formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo formulations (i.v. solution; p.o. solution; p.o. solid forms)
Study: 2222553
Drug: H1-antagonist positive
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1-antagonist positive control
Study: 12972527
Drug: Health-related quality
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-related quality of life (HRQOL) evaluation in treatment arms
Study: 4062052
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine plus decongestant
Study: 4062052
Drug: Placebo (decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (decongestant plus saline)
Study: 30466597
Drug: Nitrate re-supply
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate re-supply treatment
Study: 30466597
Drug: Nitrate starvation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate starvation treatment
Study: 30466597
Drug: Nitrate treatments
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate treatments (combined starvation and re-supply)
Study: 20202235
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac 75 mg at the end of the operation followed by 75 mg for 24 hours (150 mg/24 h)
Study: 20202235
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 1g/100 mL twice daily as postoperative analgesia
Study: 18018837
Drug: Halothane 1
Normalized name: halothane 1000 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane 1 ml, Isoflurane 1.5 ml, Sevoflurane 2.7 ml (experiment 1)
Study: 18018837
Drug: Halothane 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane 2, 4, and 6 ml (experiment 2)
Study: 18018837
Drug: Sevoflurane 5
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane 5 ml (experiment 3)
Study: 2054701
Drug: Midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3 to 0.5 mg/kg) combined with atropine sulfate (0.015 mg/kg)
Study: 2054701
Drug: Placebo (injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (injectable water) combined with atropine sulfate (0.015 mg/kg)
Study: 6356966
Drug: Terbutaline inhalations
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhalations (31 + 31 + 63 + 125 + 250 micrograms) from a pressurized aerosol with a 750 ml spacer
Study: 28137609
Drug: Dietary nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary nitrate load (300 mg) by highly concentrated beetroot juice (BJ)
Study: 21397780
Drug: 400-mg rufinamide
Normalized name: rufinamide 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-mg rufinamide tablet (reference)
Study: 21397780
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of rufinamide suspension (40 mg/mL) at 1800 rpm
Study: 21397780
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of rufinamide suspension (40 mg/mL) at 2100 rpm
Study: 21397780
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of rufinamide suspension (40 mg/mL) at 3000 rpm
Study: 18444817
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of cefuroxime 10‐30 min before inflation of the tourniquet and placebo 10 min before release of the tourniquet (standard arm)
Study: 18444817
Drug: Placebo 10‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10‐30 min before inflation of the tourniquet and 1.5 g of cefuroxime 10 min before release of the tourniquet (experimental arm)
Study: 11097670
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% with dexamethasone 0.13 mg/mL
Study: 11097670
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% with dexamethasone 0.13 mg/mL
Study: 9315064
Drug: Primary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary therapy with tamoxifen alone (n=160)
Study: 8336864
Drug: Zoladex (goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex (goserelin acetate), 3.6 mg every 28 days by subcutaneous injection
Study: 8336864
Drug: Danazol, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol, 400 mg orally twice daily for 24 weeks
Study: 3276422
Drug: Adjunctive interfascicular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive interfascicular neurolysis
Study: 28057058
Drug: Lian-Ju-Gan-Mao capsules
Normalized name: Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lian-Ju-Gan-Mao capsules (LJGMC) high-dose group
Study: 28057058
Drug: Lian-Ju-Gan-Mao capsules
Normalized name: Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lian-Ju-Gan-Mao capsules (LJGMC) medium-dose group
Study: 28057058
Drug: Lian-Ju-Gan-Mao capsules
Normalized name: Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lian-Ju-Gan-Mao capsules (LJGMC) low-dose group
Study: 12575402
Drug: Shenkang injection
Normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenkang injection (SKI)
Study: 7984593
Drug: Adjuvant endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endovascular irradiation of blood with He‐Ne laser (8-10 daily sessions lasting 30 minutes)
Study: 18603505
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 micrograms every 4 hours for a maximum of four doses)
Study: 15729173
Drug: Supplemental arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Supplemental arginine and canola oil (omega-3 and omega-9 fatty acids) twice daily
Study: 11046211
Drug: HES200 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES200 (15 ml/kg)
Study: 11046211
Drug: HES70 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES70 (15 ml/kg)
Study: 9075745
Drug: Preoperative multimodality
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative multimodality therapy (Group 1) including seven cycles of 5-fluorouracil (FU)/leucovorin (LV) chemotherapy and radiation therapy (5,040 cGy) before surgery.
Study: 9075745
Drug: Postoperative multimodality
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative multimodality therapy (Group 2) including the same chemotherapy and radiation therapy after surgery.
Study: 9075745
Drug: Preoperative multimodality
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative multimodality therapy (Group 1).
Study: 9075745
Drug: Postoperative multimodality
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative multimodality therapy (Group 2).
Study: 8422745
Drug: Fenoterol metered
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol metered dose inhaler (0.4 mg)
Study: 8422745
Drug: Fenoterol dry
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol dry powder capsules (0.4 mg)
Study: 8422745
Drug: Colforsin dry
Normalized name: Colforsin
DrugBank: Colforsin (DB02587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colforsin dry powder capsules (10.0 mg)
Study: 23470806
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus cilostazol (cilo)
Study: 23470806
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (non-cilo group)
Study: 19111610
Drug: Antioxidant (AO)
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant (AO) supplementation (200 IU of vitamin E and 500 mg ascorbic acid)